araag2/HINT huggingface dataset:
Clinical trial NCT02387216 (phase 2, status: completed)
Conditions: non-small cell lung cancer, nsclc, adenocarcinoma, heregulin
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: mm-121, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of cytologically or histologically documented adenocarcinoma
             of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC
             disease not amenable to surgery with curative intent

          -  Not received more than 2 prior systemic therapies- one of which must have been a
             platinum based regimen- for primary or recurrent disease

          -  Tissue submitted for HRG-biomarker testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Known ALK mutation

          -  Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene

          -  Received >2 prior systemic anti-cancer drug regimen for locally advanced disease

          -  Prior treatment with an anti-ErbB3 antibody

          -  CTCAE grade 3 or higher peripheral neuropathy

          -  Symptomatic CNS metastases or CNS metastases requiring steroids

          -  Any other active malignancy requiring systemic therapy

          -  Clinically significant cardiac disease
Clinical trial NCT02387606 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: placebo, jnj-53718678
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female participants must be of non-childbearing potential: postmenopausal for at least
             2 years or surgically sterile or otherwise incapable of becoming pregnant

          -  Female participants, except for postmenopausal women, must have a negative serum
             pregnancy test at screening

          -  Participants must agree to comply with contraceptive measures as mentioned in protocol

          -  Participants must be sero-suitable for respiratory syncytial virus (RSV) within 57
             days prior to inoculation

          -  Participants must be non-smokers for at least one month prior to screening and
             participants must have a negative cotinine test at screening

        Exclusion Criteria:

          -  Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at
             rest) or of risk factors for Torsade de Pointes syndrome

          -  Participants with a history or evidence of abuse of alcohol, barbiturates,
             amphetamines, recreational or narcotic drug use within the past 3 months, which in the
             Investigator's opinion would compromise participant's safety and/or compliance with
             the study procedures

          -  Participants with current human immunodeficiency virus type 1 (HIV-1) or HIV-2
             infection at screening

          -  Participants with current hepatitis A infection, or hepatitis B virus (HBV) infection,
             or hepatitis C virus (HCV) infection (confirmed by HCV antibody) at screening

          -  Participants with active acute respiratory infection at admission (Study Day -1 or -2)
Clinical trial NCT02387853 (phase 2, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: leo 90100
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria (all subjects)

          -  Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.

          -  Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.

          -  A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.

          -  PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.

          -  PGA score of at least mild on scalp at SV1, SV2 and V1.

          -  A serum albumin-corrected calcium below the upper reference limit at SV2.

        Inclusion Criteria (for subjects performing HPA axis assessment)

          -  Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.

          -  Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.

          -  PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.

          -  PGA score of at least moderate on scalp at SV1, SV2 and V1.

          -  Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before
             ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH
             challenge).

        Exclusion Criteria (all subjects):

          -  A history of hypersensitivity to any component of LEO 90100.

          -  Systemic treatment with biological therapies (marketed or not marketed), with a
             possible effect on scalp and/or body psoriasis within the following time period prior
             to V1 and during the trial:

               1. etanercept - within 4 weeks prior to V1

               2. adalimumab, infliximab - within 2 months prior to V1

               3. ustekinumab - within 4 months prior to V1

               4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior
                  to V1

          -  Systemic treatment with therapies other than biologicals, with a possible effect on
             scalp and/or body psoriasis (e.g. methotrexate, retinoids, immunosuppressants) within
             4 weeks prior to V1 or during the trial.

          -  PUVA therapy within 4 weeks prior to V1.

          -  UVB therapy within 2 weeks prior to V1 or during the trial.

        Exclusion Criteria (for subjects performing HPA axis assessment):

          -  A history of serious allergy, allergic asthma or serious allergic skin rash.

          -  Known or suspected hypersensitivity to any component of CORTROSYN® (including
             ACTH/cosyntropin/tetracosactide)

          -  Systemic treatment with corticosteroids (including inhaled and nasal steroids) within
             12 weeks prior to SV2 or during the trial.

          -  Oestrogen therapy (including contraceptives) or any other medication known to affect
             cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.
Clinical trial NCT02392780 (phase 2, status: unknown status)
Conditions: acute-graft-versus-host disease
ICD codes: D89.810, D89.812
Drugs: cannabidiol, methylprednisolone, calcineurin inhibitor
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Patients 18 years or older

          2. After allogeneic transplantation

          3. Grade III or IV acute GVHD

          4. No psychiatric contra-indication

          5. Informed consent

        Exclusion Criteria:

          1. History of psychosis

          2. Asthma

          3. Known allergy to cannabis constituents
Clinical trial NCT02395978 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: pdc-1421 capsule, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Outpatients aged 20-65 years

          2. Subjects must be able to understand and willing to sign informed consent

          3. Female subjects of child-bearing potential must test negative to pregnancy and use
             appropriate birth control method from the beginning of study to the 15 days later
             after ending of study

          4. Met criteria for MDD without psychotic features as defined by the Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition Text Revision® (DSM-IV-TR) and
             confirmed by use of the Mini International Neuropsychiatric Interview (MINI).

          5. 17-item HAM-D (Hamilton Rating Scale for Depression) total score ≧20 and CGI (Clinical
             Global Impression) total score ≧4

        Exclusion Criteria:

          1. Have a current or previous major psychiatric disorders which be defined to be per the
             DSM-IV-TR, including obsessive-compulsive disorder, posttraumatic stress disorder,
             bipolar I or II, manic or hypomanic episode, schizophrenia, major Axis II disorders
             which might compromise the study, and major depression with psychotic symptoms, mental
             retardation.

          2. Use of any treatment for MDD in the last 2 weeks before visit 1 (4 weeks for
             fluoxetine).

          3. Use of psychoactive drugs within the last 2 weeks before visit 1 other than that
             subjects had insomnia who need the treatment as determined by the Investigator.

          4. Subjects who were non-responsive to two or more courses of antidepressant medications
             given an adequate dosage for symptom treatment within four weeks, or by the judgment
             of the investigator considered to have treatment resistant depression (TRD), or a
             history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or
             psychosurgery within the last year.

          5. Have a history of any seizure disorder.

          6. Any clinically significant abnormal vital sign, ECG, laboratory values as determined
             by the investigator which might interfere with the study.

          7. Any organic disorder caused u medical related depression which cannot be under
             well-controlled such as clinically significant in neurological, gastrointestinal,
             renal, hepatic, cardiovascular, respiratory, metabolic, endocrine, hematological or
             other major disorders

          8. Have a high suicidal risk as measured by MINI.

          9. Have a history of substance abuse within the past 6 months or a positive urine drug
             screen for any substance of abuse at visit 1.

         10. Have a history of severe allergies to more than 1 class of medication or multiple
             adverse drug reactions.
Clinical trial NCT02397694 (phase 2, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: bic, f/taf, dtg, bic placebo, dtg placebo, b/f/taf
SMILES: OC1=C2N(C[C@H]3O[C@@H]4CC[C@@H](C4)N3C2=O)C=C(C(=O)NCC2=C(F)C=C(F)C=C2F)C1=O, CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)

          -  Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening

          -  Screening genotype report provided by Gilead Sciences must show sensitivity to
             tenofovir (TFV) and emtricitabine (FTC)

          -  Adequate renal function as measured by estimated glomerular filtration rate ≥ 70
             mL/min according to the Cockcroft-Gault formula

          -  CD4+ cell count ≥ 200 cells/µL at screening

        Key Exclusion Criteria:

          -  A new AIDS-defining condition diagnosed within the 30 days prior to screening as
             defined in the study protocol

          -  Prior use of antiretrovirals in the setting of pre-exposure prophylaxis (PrEP) or post
             exposure prophylaxis (PEP)

          -  Chronic hepatitis B virus (HBV) infection

          -  Hepatitis C infection (Individuals who are hepatitis C virus (HCV) Ab positive, but
             have a documented negative HCV RNA, are eligible)

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to baseline

          -  Participation in any other clinical trial without prior approval from the sponsor is
             prohibited while participating in this trial

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02399137 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: mm-141, placebo, gemcitabine, nab-paclitaxel
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not
             eligible.

          -  Patient must have received no prior radiotherapy, surgery, chemotherapy, or
             investigational therapy for the treatment of metastatic disease.

          -  Blood sample sent for free IGF-1 testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Patients who only present with localized disease

          -  Patients with CNS malignancies (primary or metastatic)

          -  Clinically significant cardiac disease
Clinical trial NCT02399592 (phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, tocotrinol
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.

          -  Prior treatment with at least two different cytostatic regimens including platinum.

          -  Progression on previous treatment.

          -  Measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria.

          -  Age ≥ 18 years.

          -  Performance stage 0-2.

          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior
             to inclusion):

               -  WBC ≥ 3.0 * 10^9/l or neutrophils (ANC) ≥ 1.5 * 109/l

               -  Platelet count ≥ 100 * 10^9/l

               -  Hemoglobin ≥ 6 mmol/l

               -  Serum bilirubin < 2.0 * ULN

               -  Serum transaminase ≤ 2.5 * ULN

               -  Serum creatinine ≤ 1.5 ULN

          -  Urine dipstick for protein <2+. If the dipstick shows protein ≥2+ 24 hour urine
             testing must be made with protein contents < 1 g.

          -  Written informed consent.

        Exclusion Criteria:

          -  Other malignant diseases within 5 years prior to inclusion in the study, except
             curatively treated basal cell or squamous cell carcinoma of the skin and other types
             of cancer with minimal risk of recurrence.

          -  Other experimental therapy or participation in another clinical trial within 28 days
             prior to treatment initiation.

          -  Underlying medical disease not adequately treated (diabetes, cardiac disease).

          -  Uncontrolled hypertension (BT >150/100 despite antihypertensive treatment).

          -  Surgery, incl. open biopsy, within 4 weeks prior to first dose of bevacizumab.

          -  Non-healing wounds or fractures.

          -  Cerebral vascular attack, transient ischemic attack or subarachnoidal hemorhage within
             6 months before start of treatment.

          -  Clinically significant cardiovascular disease, including:

               -  Myocardial infarction or unstable angina within 6 months before start of
                  treatment

               -  New York heart Association (NYHA) class ≥ 2

               -  Poorly controlled cardiac arrhythmia despite medication

               -  Periferal vascular disease grade ≥ 3

          -  Allergy to the active substance or any of the auxiliary agents

          -  Bleeding tumor

          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at
             screening is mandatory.

          -  Fertile patients not willing to use effective methods of contraception during
             treatment and for 6 months after the end of treatment
Clinical trial NCT02399709 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: simvastatin, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age >=18 and <=70 years,

          -  Smoking more than 10 cigarettes per day for at least 1 year,

          -  Motivated to quit smoking,

          -  Without legal tutors or subordination,

          -  Affiliated to a health insurance system as required by the French law on biomedical
             research,

          -  Written informed consent for participation in the study.

        Exclusion Criteria:

          -  Age < 18 or > 70 years,

          -  Presenting a contraindication to simvastatin use,

          -  With depression and/or psychosis and/or cognitive disorder and/or mental retardation
             or chronic use of medications for these disorders,

          -  Substance use disorder other than smoking,

          -  More than 3 months of abstinence from cigarette smoking in the previous year,

          -  Use of nicotine replacement therapy, bupropion, varenicline on last 3 months,

          -  Use of clonidine or nortriptyline on last 3 months,

          -  Undergoing on last 3 months' cognitive-behavioral therapy for smoking cessation,

          -  Premenopausal women without contraception.
Clinical trial NCT02403778 (phase 2, status: active, not recruiting)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: vesanoid, ipilimumab
SMILES: C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O, COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over the age of 18 year.

          -  Patients diagnosed with advanced melanoma.

          -  Patients that are considered candidates for ipilimumab therapy.

          -  Patients able to understand and willing to sign a written informed consent documents.

          -  Patients willing to have regular blood draws, one before treatment and four during or
             after treatment.

        Exclusion Criteria:

          -  Patients under the age of 18.

          -  Patients with Stage I or II, melanoma who are not candidates for Ipilimumab.

          -  Patients that have received systemic treatments within four weeks prior to the
             beginning of treatment.

          -  Women that are pregnant or nursing.

          -  Patients taking immunosuppressive medications.

          -  Patients with active autoimmune disease.

          -  Patients with known sensitivity to retinoic acid derivatives.

          -  Patients with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or
             bilirubin > 2.5 × ULN.
Clinical trial NCT02405013 (phase 2, status: completed)
Conditions: hepatitis c, hiv infection
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9, Z21
Drugs: sofosbuvir, ribavirin, sofosbuvir, ledipasvir
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age≥18 years

          -  Confirmed G1, G2 or G4 HCV infection

          -  Plasma HCV-RNA ≥1000 IU/mL

          -  No history of HCV treatment of any kind

          -  Willingness to use a birth control method (hormonal or intrauterine device for women,
             condoms for men), starting before HCV treatment initiation and continued until 4months
             (women) and 7 months (men) after end of treatment.

          -  Weight ≥40 kg and ≤125 kg

        For patients infected with HIV :

          -  Confirmed HIV-1 infection

          -  Stable HIV treatment for at least 8 weeks with two NRTIs (tenofovir or abacavir, and
             lamivudine or emtricitabine) and a third agent (raltegravir, lopinavir/ritonavir,
             atazanavir/ritonavir, darunavir/ritonavir, efavirenz, nevirapine)

          -  Current CD4+ lymphocytes count ≥100/mm3

          -  Current plasma HIV-1 RNA <200 copies/mL

        Exclusion Criteria:

        For each patient:

          -  Cirrhosis classified Child-Pugh B or C

          -  Co-infection by the Hepatitis B virus

          -  Pregnant or breastfeeding ongoing

          -  History of transplantation of organs or tissues

          -  Progressive Cancer, including hepatocellular carcinoma

          -  Epilepsy

          -  Sickle Cell Disease

          -  A history of myocardial infarction or other severe heart disease

          -  Excessive consumption of alcohol or drug users, in the absence of substitution by
             methadone, a stable weaning for more than three months should be required

          -  Ongoing Participation in another clinical trial

          -  Contraindications to the Sofosbuvir as defined in the Summary of Product
             Characteristics

          -  At least one of the following laboratory abnormalities:

        Haemoglobin <10 g / 100 ml (woman) <11 g / 100 ml (man) Platelet count <50,000 / mm3
        polymorphonuclear neutrophils rate <750 / mm3 Creatinine clearance <50ml / min

        For patients infected with HIV:

          -  Severe opportunistic infections in the last 6 months

          -  Poor adherence to antiretroviral treatment history

          -  Use of antiretroviral drugs other than those permitted in the test
Clinical trial NCT02405364 (phase 2, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: carfilzomib/lenalidomide/dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with multiple myeloma based on the new International Myeloma
             Working Group

          -  Subjects must have symptomatic myeloma with at least one CRAB criteria

          -  Subjects must not have been treated previously with any systemic therapy for multiple
             myeloma

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  Acute active infection requiring treatment

          -  Treatment by localized radiotherapy if the interval between the end of radiotherapy
             and initiation of protocol therapy lower than 2 weeks

          -  Treatment by corticosteroids if exceed the equivalent of 160 mg of dexamethasone in a
             2-week period before initiation therapy

          -  Subjects not eligible for high dose therapy